Before starting DMARDs II, which tests are recommended?

Before starting DMARDs II, which tests are recommended?

• A. TB test and HBV test
• B. HIV test only
• C. Hepatitis C test only
• D. No baseline testing required

Answer: (A)

The key idea here is baseline infectious disease screening before starting DMARDs to prevent complications from immunosuppression. DMARDs can dampen the immune system enough to allow latent infections to reactivate, so identifying these infections beforehand is crucial. Testing for latent tuberculosis is essential because immunosuppressive therapies, especially TNF inhibitors, can reactivate latent TB. A TB test—either the tuberculin skin test or an interferon-gamma release assay—helps detect latent infection so it can be treated before or alongside starting DMARDs. Hepatitis B testing is also important because HBV can reactivate under immunosuppression. Baseline serology (HBsAg, anti-HBs, and anti-HBc) determines whether there is an active infection, prior exposure, or immunity, guiding monitoring and possible antiviral prophylaxis during therapy. Other tests like HIV or hepatitis C may be considered in certain cases, but the recommended baseline set commonly includes TB and HBV testing to address the most risk-prone infections associated with DMARDs. No baseline testing is not appropriate.

The key idea here is baseline infectious disease screening before starting DMARDs to prevent complications from immunosuppression. DMARDs can dampen the immune system enough to allow latent infections to reactivate, so identifying these infections beforehand is crucial.

Testing for latent tuberculosis is essential because immunosuppressive therapies, especially TNF inhibitors, can reactivate latent TB. A TB test—either the tuberculin skin test or an interferon-gamma release assay—helps detect latent infection so it can be treated before or alongside starting DMARDs.

Hepatitis B testing is also important because HBV can reactivate under immunosuppression. Baseline serology (HBsAg, anti-HBs, and anti-HBc) determines whether there is an active infection, prior exposure, or immunity, guiding monitoring and possible antiviral prophylaxis during therapy.

Other tests like HIV or hepatitis C may be considered in certain cases, but the recommended baseline set commonly includes TB and HBV testing to address the most risk-prone infections associated with DMARDs. No baseline testing is not appropriate.